Cart
sales@molnova.com
GR 103691
CAS No. 162408-66-4
GR 103691( —— )
Catalog No. M23720 CAS No. 162408-66-4
GR 103691 is a potent, selective dopamine D3 receptor antagonist (Ki: 0.4 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 34 | In Stock |
|
| 5MG | 55 | In Stock |
|
| 10MG | 91 | In Stock |
|
| 25MG | 186 | In Stock |
|
| 50MG | 295 | In Stock |
|
| 100MG | 478 | In Stock |
|
| 500MG | 1062 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGR 103691
-
NoteResearch use only, not for human use.
-
Brief DescriptionGR 103691 is a potent, selective dopamine D3 receptor antagonist (Ki: 0.4 nM).
-
DescriptionGR 103691 is a potent, selective dopamine D3 receptor antagonist (Ki: 0.4 nM). It shows more than 100-fold selectivity for human dopamine human (h)D3 over hD4 and hD1 sites.
-
In VitroGR 103691 shows marked affinity for serotonin1A (5-HT1A) receptors (Ki of 5.8 nM) and α-1 adrenoceptors (Ki of 12.6 nM).
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorD3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number162408-66-4
-
Formula Weight485.62
-
Molecular FormulaC30H35N3O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESO=C(C1=CC=C(C2=CC=C(C(C)=O)C=C2)C=C1)NCCCCN3CCN(C4=CC=CC=C4OC)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Audinot V, et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther. 1998 Oct;287(1):187-97.
molnova catalog
related products
-
UCM-1306
UCM-1306 is a potent and orally active allosteric modulator (PAM) of the human dopamine D1 receptor. It increases the maximal effect of endogenous dopamine (DA) in both human and mouse D1 receptors.
-
Abaperidone
Abaperidone is a potent 5-HT2A receptor and dopamine D2 receptor antagonist with an IC50 of 6.2 for 5-HT2A receptors and 17 nM for dopamine D2 receptors.
-
CCT241736
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant mutants including FLT3-ITD and FLT3.
